Underdog obesity drug performs well in Phase II study

Altimmune has shown that the company’s weight loss drug pemvidutid predominantly provides weight loss from lost fat mass, rather than muscle.
Photo: Annette Riedl/AP/Ritzau Scanpix
Photo: Annette Riedl/AP/Ritzau Scanpix

Altimmune presented new data from the Phase II Momentum trial investigating the efficacy of the experimental drug pemvidutide at the American Diabetes Association’s annual meeting on Sunday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading